Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="236949"/>
<meta>
<versionId value="62"/>
<lastUpdated value="2024-12-16T14:25:12.201Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"/>
</meta>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="part-of"/>
<resourceReference>
<type value="Composition"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-conversion-report"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
</resourceReference>
</valueRelatedArtifact>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236949. Revised 2024-12-14. Available at: https://fevir.net/resources/Group/236949. Computable resource at: https://fevir.net/resources/Group/236949#json."/>
</valueRelatedArtifact>
</extension>
<url value="https://fevir.net/resources/Group/236949"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="urn:ietf:rfc:3986"/>
<value value="https://fevir.net/FOI/236949"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<title value="SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
<status value="active"/>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<description value="Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors"/>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="ExposureGroup"/>
<display value="ExposureGroup"/>
</coding>
</valueCodeableConcept>
</useContext>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<type value="person"/>
<membership value="enumerated"/>
<combinationMethod value="all-of"/>
<characteristic>
<code>
<text value="Member of"/>
</code>
<valueReference>🔗
<reference value="Group/236947"/>
<type value="Group"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-population-group-85394-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="Adults with type 2 diabetes and CVD and CKD"/>
</valueReference>
<exclude value="false"/>
<description value="inclusion in Adults with type 2 diabetes"/>
</characteristic>
<characteristic>
<code>
<text value="Exposed to"/>
</code>
<valueReference>🔗
<reference value="Group/236769"/>
<type value="Group"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-intervention-85394-I-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors"/>
</valueReference>
<exclude value="false"/>
<description value="received SGLT2 inhibitors"/>
</characteristic>
</Group>